Rezolute, Inc. (NASDAQ:RZLT) Shares Sold by Altium Capital Management LLC

Altium Capital Management LLC cut its holdings in Rezolute, Inc. (NASDAQ:RZLT) by 0.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,694,000 shares of the company’s stock after selling 6,000 shares during the quarter. Rezolute comprises 2.4% of Altium Capital Management LLC’s investment portfolio, making the stock its 15th biggest holding. Altium Capital Management LLC’s holdings in Rezolute were worth $8,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in shares of Rezolute during the 4th quarter valued at approximately $2,408,000. Geode Capital Management LLC increased its stake in Rezolute by 39.0% in the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after purchasing an additional 137,905 shares in the last quarter. Exome Asset Management LLC raised its holdings in Rezolute by 24.7% during the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock worth $1,707,000 after purchasing an additional 69,656 shares during the last quarter. Barclays PLC purchased a new stake in Rezolute during the fourth quarter worth $314,000. Finally, ExodusPoint Capital Management LP acquired a new stake in Rezolute in the fourth quarter valued at $277,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

Insider Activity at Rezolute

In other news, CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the purchase, the chief financial officer now directly owns 237,900 shares of the company’s stock, valued at approximately $687,531. This trade represents a 4.39 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Nevan C. Elam bought 12,302 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average cost of $2.85 per share, with a total value of $35,060.70. Following the transaction, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. This represents a 5.81 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 39,060 shares of company stock worth $130,694. 18.39% of the stock is owned by company insiders.

Rezolute Stock Up 4.2 %

Shares of Rezolute stock opened at $2.75 on Friday. Rezolute, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $6.19. The business’s fifty day moving average is $3.51 and its two-hundred day moving average is $4.50. The firm has a market cap of $166.47 million, a PE ratio of -2.25 and a beta of 0.97.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Equities research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on RZLT shares. Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a report on Monday, February 10th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Thursday, February 13th. Finally, JMP Securities lifted their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Rezolute currently has a consensus rating of “Buy” and an average target price of $24.38.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.